Abstract
The insulin-like growth factors (IGFs) acting via the type I IGF receptor (IGF-1R) regulate cancer cell proliferation, survival, metabolism and metastasis. Drugs targeting the IGF-1R are being tested in human clinical trials for cancer therapy and it seems likely that this class of drugs could be approved soon. Recent data suggests that insulin receptor, which is closely related to IGF-1R, should also be targeted to maximally inhibit the system. Furthermore, biomarkers that identify patients whose tumors are driven by IGF-1R and biomarkers that allow monitoring or prediction of response are needed. This article reviews the different drugs against IGF-1R that are being tested and how this receptor pathway can be optimally targeted for cancer therapy with an emphasis on breast cancer therapy.
Keywords: Breast cancer, targeted therapy, insulin-like growth factors, IGF-1R, antibodies, small molecule inhibitors, clinical trials
Current Drug Targets
Title: Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Volume: 11 Issue: 9
Author(s): Deepali Sachdev
Affiliation:
Keywords: Breast cancer, targeted therapy, insulin-like growth factors, IGF-1R, antibodies, small molecule inhibitors, clinical trials
Abstract: The insulin-like growth factors (IGFs) acting via the type I IGF receptor (IGF-1R) regulate cancer cell proliferation, survival, metabolism and metastasis. Drugs targeting the IGF-1R are being tested in human clinical trials for cancer therapy and it seems likely that this class of drugs could be approved soon. Recent data suggests that insulin receptor, which is closely related to IGF-1R, should also be targeted to maximally inhibit the system. Furthermore, biomarkers that identify patients whose tumors are driven by IGF-1R and biomarkers that allow monitoring or prediction of response are needed. This article reviews the different drugs against IGF-1R that are being tested and how this receptor pathway can be optimally targeted for cancer therapy with an emphasis on breast cancer therapy.
Export Options
About this article
Cite this article as:
Sachdev Deepali, Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy, Current Drug Targets 2010; 11 (9) . https://dx.doi.org/10.2174/138945010792006816
DOI https://dx.doi.org/10.2174/138945010792006816 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME
Anti-Cancer Agents in Medicinal Chemistry Antibacterial Peptides and Gastrointestinal Diseases
Current Pharmaceutical Design Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Editorial (Another Year of Prosperity for Current Molecular Medicine)
Current Molecular Medicine Macrolides as Immunomodulatory Agents: Review and Future Directions
Medicinal Chemistry Reviews - Online (Discontinued) Meet Our Editorial Board Member
Current Computer-Aided Drug Design Editorial: Azoles in Anticancer Research: Rational Approaches, Design Strategies, Recent Insights and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Drug Binding Domains of MRP1 (ABCC1) as Revealed by Photoaffinity Labeling
Current Medicinal Chemistry - Anti-Cancer Agents Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls
Current Drug Metabolism Hedgehog Signaling and Urological Cancers
Current Drug Targets Recent Advances in Curcumin Nanocarriers for the Treatment of Different Types of Cancer with Special Emphasis on In Vitro Cytotoxicity and Cellular Uptake Studies
Nanoscience & Nanotechnology-Asia Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on DNA & Gene Sequences Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?
Current Protein & Peptide Science